Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311956 | 1.00 | USP5 (0.68) | USP5TSHRSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL31303320 | 0.86 | USP5 (0.69) | USP5TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL21459433 | 0.86 | USP5 (0.69) | USP5TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL21459432 | 0.86 | USP5 (0.69) | USP5TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL21476275 | 0.84 | USP5 (0.66) | USP5TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6385632 | 0.83 | USP5 (0.48) | USP5TSHRALDH1A1LMNAMAPT | |
| SCHEMBL79412 | 0.83 | USP5 (0.48) | USP5TSHRALDH1A1LMNAMAPT | |
| SCHEMBL77994 | 0.83 | GCK (0.48) | USP5TSHRL3MBTL1LMNAKDM4E | |
| SCHEMBL87330 | 0.83 | GCK (0.48) | USP5TSHRL3MBTL1LMNAKDM4E | |
| SCHEMBL312165 | 0.81 | USP5 (1.00) | USP5TSHRSMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| CN-100503572-C | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-06-24 | — | — | CN | disclosed |
| CN-101348455-A | Aspartic acid specificity cysteine proteinase inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-01-21 | — | — | CN | disclosed |
| CN-100415718-C | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2008-09-03 | — | — | CN | disclosed |
| CN-1675184-A | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1539701-A1 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-15 | — | — | US | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
| CN-1420872-A | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072850-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP2 | USP5 759/4885TSHR 4796/4885SMN1; SMN2 655/4885 |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | USP5 590/4885TSHR 4813/4885SMN1; SMN2 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.